204139-58-2

Basic information

• Product Name: (S)-N-((S)-1-Carbamoyl-2-cyclohexyl-ethyl)-3-(2-ethylamino-acetylamino)-succinamic acid benzyl ester
• Synonyms: (S)-N-((S)-1-Carbamoyl-2-cyclohexyl-ethyl)-3-(2-ethylamino-acetylamino)-succinamic acid benzyl ester
• CAS NO: 204139-58-2
• Molecular Weight: 460.574
• Mol File: 204139-58-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-N-((S)-1-Carbamoyl-2-cyclohexyl-ethyl)-3-(2-ethylamino-acetylamino)-succinamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-((S)-1-Carbamoyl-2-cyclohexyl-ethyl)-3-(2-ethylamino-acetylamino)-succinamic acid benzyl ester(204139-58-2)
• EPA Substance Registry System: (S)-N-((S)-1-Carbamoyl-2-cyclohexyl-ethyl)-3-(2-ethylamino-acetylamino)-succinamic acid benzyl ester(204139-58-2)

Safety Data

• Hazardous Substances Data: 204139-58-2(Hazardous Substances Data)

Upstream product

• 204139-57-1 (S)-3-[2-(tert-Butoxycarbonyl-ethyl-amino)-acetylamino]-N-((S)-1-carbamoyl-2-cyclohexyl-ethyl)-succinamic acid benzyl ester 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 145232-34-4 L-cyclohexylalanine amide 
• 134676-62-3 (S)-3-Amino-N-((S)-1-carbamoyl-2-cyclohexyl-ethyl)-succinamic acid benzyl ester 
• 118517-08-1 (S)-3-tert-Butoxycarbonylamino-4-isopropoxycarbonyloxy-4-oxo-butyric acid benzyl ester 
• 145232-33-3 (S)-3-tert-Butoxycarbonylamino-N-((S)-1-carbamoyl-2-cyclohexyl-ethyl)-succinamic acid benzyl ester 

Relevant articles and documents

Design of a new class of orally active fibrinogen receptor antagonists

The integrin receptor recognition sequence Arg-Gly-Asp was successfully used as a template from which to develop a series of potent, selective, orally active, peptide-based fibrinogen receptor antagonists with a long duration of action. Simple modifications centered on the Arg and Gly residues quickly led to a modified peptide (1) with significantly enhanced ability to inhibit in vitro platelet aggregation. Substitution of the guanidino group in 1 by piperidine provided 3, which showed not only a further increase in potency but also a modest degree of oral efficacy. Finally, exploration of the nature of the C-terminal amino acid, with respect to its side-chain functionality and the carboxy terminus, yielded a group of molecules that showed excellent in vitro potency for inhibiting platelet aggregation, excellent integrin selectivity, a high level of oral efficacy, and an extended duration of action.